Back to Search Start Over

Bevacizumab for eye diseases - Legal, regulatory, and ethical overview

Authors :
Jose, Vinu
Radhakrishna, Swetha
Pipalava, Parag
Singh, Inderjeet
Source :
Indian Journal of Pharmacology. Nov-Dec, 2019, Vol. 51 Issue 6, 377
Publication Year :
2019

Abstract

Byline: Vinu. Jose, Swetha. Radhakrishna, Parag. Pipalava, Inderjeet. Singh Vascular endothelial growth factor (VEGF) inhibitors, ranibizumab, aflibercept, and pegaptanib are approved treatments for certain eye diseases that occurs especially in [...]

Subjects

Subjects :
United States. Food and Drug Administration -- Ethical aspects
Cancer treatment
Ophthalmic agents -- Ethical aspects
Ramucirumab
Bevacizumab -- Ethical aspects
Vascular endothelial growth factor
Eye diseases
Pegaptanib
Endothelium
Angiogenesis inhibitors
Endothelial growth factors
Aflibercept
Ranibizumab
Diseases
Health

Details

Language :
English
ISSN :
02537613
Volume :
51
Issue :
6
Database :
Gale General OneFile
Journal :
Indian Journal of Pharmacology
Publication Type :
Academic Journal
Accession number :
edsgcl.612669373

Tools

Authors Abstract Subjects Details